Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
June 30th, 2025
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Category: Corporate/Financial News
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
June 17th, 2025
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
June 16th, 2025
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
May 29th, 2025
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
May 15th, 2025
APDN Reminds Shareholders to Vote Ahead of Special Meeting on February 14
February 11th, 2025
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
January 8th, 2025
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
December 17th, 2024
APDN to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
December 16th, 2024